Table 1.
Gene | Protein(s) | Functional Category |
Primary Protein Function | Secondary Protein Function | Disease Relevance | Mechanism of Expression of Second Cistron | Bicistronic Organization |
Refs |
---|---|---|---|---|---|---|---|---|
TCP-Binding Protein |
PRO1 (8.9kDa) / PRO2 (9.5kDa) |
1 | PRO1: Interacts with PRO2 to make a low-affinity phencyclidine binding entity that is part of a synaptic membrane complex |
PRO2: Interacts with PRO1 to make a low-affinity phencyclidine binding entity that is part of a synaptic membrane complex |
None reported | Putative IRES sequence between PRO1 ORF and PRO2 ORF |
Tandem | [20] |
FFAR1 | GPR40 (31kDa) / GPR41 (38kDa) |
2 | GPR40: Long-chain fatty acid receptor | GPR41: Short-chain fatty acid receptor |
None reported | IRES in the coding region of FFAR1 encodes GPR41 |
Tandem | [21–24] |
meloe | MELOE-1 (4.3 kDa) / MELOE-2 (5.1 kDa)/ MELOE-3 (5.9 kDa) |
2 | MELOE-3: No known function; Poor immunogenicity, but is expressed in melanoma cells and normal melanocytes |
MELOE-1: No known function; T cell antigen selectively expressed in melanoma cells MELOE-2: No known function; T cell antigen selectively expressed in melanoma cells |
Potential target for T cell immune therapy for melanoma |
IRES upstream of the ORFs of MELOE-1 and MELOE-2; MELOE-3 is produced by cap- dependent translation |
Tandem | [15, 16, 25] |
MTPN | Myotrophin (12.9 kDa) / MPD6 (6.4 kDa) |
3 | Myotrophin: Allows dimerization of NFκB in cardiac tissue |
MPD6: No known function; antigen upregulated in response to interferon-α (IFN-α) |
Myotrophin induces cardiac hypertrophy; MPD6 elicits humoral immune response in some cancers |
MPD6 antigen ORF is located in the 3' UTR region of the myotrophin gene and is translated by an IRES located upstream |
Tandem | [30] |
Connexin 43 | Cx43 (43kDa) / Cx43-CT (20kDa) |
3 | Cx43: Highly abundant connexin with junctional and non-junctional function |
Cx43-CT: Implicated in autoregulating the trafficking of Cx43 |
Hypoplastic left heart syndrome 1, Oculodentodigital dysplasia, Syndactyly type III Craniometaphyseal dysplasia |
Putative IRES or Cap-dependent internal translation |
Overlapping | [45, 46] |
Connexin 55.5 | Cx55.5 (56kDa) / CT-11 (16kDa) |
3 | Cx55.5: A connexin exclusively expressed in horizontal cells |
CT-11: Has nuclear translocation and may be involve in regulating light- dependent plasticity |
Mutations in human homolog associated with cataracts |
Putative IRES upstream of ATG at nucleotide position 1201 |
Overlapping | [47] |
pVHL-19 | pVHL-30 (30kDa) / pVHL-19 (19kDa) |
3 | pVHL-30: Tumor suppressor residing in cytosol |
pVHL-19: Comparable tumor suppressor in nucleus and cytoplasm with possibly different molecular substrates |
von Hippel-Lindau disease | Mechanism not investigated | Overlapping | [48, 49] |
CdcL1/CdcL2 (PITSLRE genes) |
p110 (PITSLRE) (110 kDa) / p58(PITSLRE) (58kDa) cyclin- dependent kinase isoforms |
3 | p110 (PITSLRE): Regulates transcriptional processing by binding elongation factors and RNA-binding proteins |
p58 (PITSLRE): Binds cyclin D3 in G2/M phases of the cell cycle |
None reported | Increased translation of p58 during G2/M phase due to Unr and phosphorylated eIF-2α binding via IRES near C-terminal end of p110 |
Overlapping | [26] |
SNRPN/SNURF | SmN (24.6kDa) / SNURF (8.4kDa) |
3 | SmN: Splicing factor important for RNA processing |
SNURF: Potentially implicated in the regulatory mechanism behind gene imprinting |
Prader-Willi syndrome; Angelman syndrome |
Mechanism not investigated | Tandem | [50] |
GDF1-LASS1 | GDF1 (39kDa) / LASS1 (39kDa) |
3 | GDF1: TGFβ superfamily member implicated in cell growth and differentiation with role in left-right patterning and mesoderm induction |
LASS1 (CerS1) ceramide synthase: TGFβ superfamily member implicated in cell growth and differentiation; catalyzes the synthesis of C18 ceramide in a fumonisin B1- independent manner |
GDF1: cardiovascular malformations; LASS1: progressive myoclonic epilepsy-8 (EPM8) |
Mechanism not Investigated | Tandem | [51] |
CACNA1A | a1A (220kDa) / a1ACT (75kDa) |
3 | a1A: Voltage-gated calcium channel subunit involved in pre and postsynaptic Ca2+ signaling, gene expression |
a1ACT: Transcription factor important for expression of neural and Purkinje cell development genes |
Spinocerebellar ataxia type 6 (SCA6), Episodic ataxia type 2 (EA-2), Familial hemiplagic migraine type 1 (FHM-1), Epilepsy |
a1ACT is made via an IRES in the C-terminal coding region of CACNA1A |
Overlapping | [27–29] |
Notch2 | Notch2 (265kDa) / N2ICD (v-Notch2) (70kDa) |
4 | Notch2: Cell surface transmembrane receptor involved in cell fate decision during development by release of N2ICD |
N2ICD: The intracellular domain decoupled and independent of Notch2 surface ligand |
Hajdu-Cheney Syndrome; Alagille syndrome |
Proposed dual mechanism of second cistron initiation: ribosomal reinitiation and IRES both equally contributing to expression of N2ICD |
Overlapping | [31–37] |
Her2 | HER2 (185 kDa) / HER2 CTF (70 kDa) |
4 | HER2: Tyrosine kinase receptor canonically known to act in secretory and endocytic pathways but also acts within the cell nucleoplasm and nucleus |
HER2 CTFs: C-terminal fragments that encompass the transmembrane and cytoplasmic domains of full length HER2, are associated with nodal metastasis, and localize to the cytoplasm and nucleus of cells |
Hereditary breast cancer, cancer metastasis, tumor development |
Hypothesized IRES within coding region (not confirmed); two methionines at positions 611 and 687 act as initiators of translation for CTFS |
Overlapping | [38] |